In renal cell cancer, overexpression of CAIX is common and the possible role of CAIX targeting antibodies (WX-G250, Rencarex®) is currently being evaluated in phase III trials for this entity [52]. This evidence concerns the gene CA9 and renal cell adenocarcinoma.